Bright Minds Biosciences Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Bright Minds Biosciences Inc (DRUG) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Bright Minds Biosciences Inc vs Its Competitors
- Scale: Bright Minds Biosciences Inc ranks #252 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
API endpoints for this dataset
Bright Minds Biosciences Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Bright Minds Biosciences Inc | - | - | - | No |
| Competitors combined (15) | ||||
| High-Confidence Competitors (24) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
DRUG Stock Performance relative to its Competitors
DRUG Stock Performance relative to High-Confidence Competitors
DRUG Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Definium Therapeutics Inc | 282.9% | Outperformed |
| 2 | Alto Neuroscience Inc | 282.9% | Outperformed |
| 3 | Compass Pathways Plc | 282.9% | Outperformed |
| 4 | Indivior Pharmaceuticals Inc | 282.9% | Outperformed |
| 5 | Xenon Pharmaceuticals Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Bright Minds Biosciences Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Bright Minds Biosciences Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Bright Minds Biosciences Inc |
155.51 | - |
 Indivior Pharmaceuticals Inc |
4,426.16 | 1,376.00 |
 Xenon Pharmaceuticals Inc |
4,122.85 | 13.17 |
 Definium Therapeutics Inc |
3,834.12 | - |
 Ataibeckley Inc |
2,651.54 | 4.47 |
 Compass Pathways Plc |
1,503.75 | - |
| SUBTOTAL | 18,770.14 | 1,712.75 |
Sign in to see all competitors of Bright Minds Biosciences Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Bright Minds Biosciences Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Bright Minds Biosciences Inc's Competitors Named by the Company
Competitive relationships identified from Bright Minds Biosciences Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Otsuka Pharmaceutical | Company report | 85% |
| SK Life Science | Company report | 85% |
| UCB | Company report | 85% |
| Eli Lilly and Co. | Company report | 85% |
| Jazz Pharmaceuticals | Company report | 85% |
| Praxis Therapeutics | Company report | 85% |
| Takeda Pharmaceutical Co. Ltd | Company report | 85% |
| Bristol Myers Squibb Co. | Company report | 85% |
| H. Lundbeck A/S | Company report | 85% |
| Merck | Company report | 85% |
| Ovid Therapeutics | Company report | 85% |
| Xenon Pharmaceuticals | Company report | 85% |
| AstraZeneca | Company report | 85% |
| GlaxoSmithKline | Company report | 85% |
| Johnson & Johnson | Company report | 85% |
| Sanofi | Company report | 85% |
| Eisai | Company report | 85% |
| Harmony Biosciences | Company report | 85% |
| Novartis | Company report | 85% |
| Pfizer Inc. | Company report | 85% |
| Supernus Pharmaceuticals | Company report | 85% |
| AbbVie Inc. | Company report | 85% |
| Biocodex | Company report | 85% |
| Marinus Pharmaceuticals | Company report | 85% |
| Amgen | Company report | 85% |
| Novo Nordisk A/S | Company report | 85% |
| Alkermes Plc | Company report | 85% |
| Sunovion Pharmaceuticals Inc. | Company report | 85% |
| Orexigen Therapeutics, Inc. | Company report | 85% |
| Teva Pharmaceutical Industries Ltd. | Company report | 85% |
| Allergan Plc | Company report | 85% |
| H. Lundbeck | Company report | 85% |
| Enveric Biosciences Inc | Company report | 85% |
| Cybin Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Bright Minds Biosciences Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Bright Minds Biosciences Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Indivior Pharmaceuticals Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Bright Minds Biosciences Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Bright Minds Biosciences Inc | 156 | - | -164,345 |
| Indivior Pharmaceuticals Inc | 4,426 | 1,376,000 | 451,000 |
| Xenon Pharmaceuticals Inc | 4,123 | 35,597 | -1,105,932 |
| Definium Therapeutics Inc | 3,834 | - | - |
| Ataibeckley Inc | 2,652 | 22,144 | -3,308,347 |
| Compass Pathways Plc | 1,504 | - | -1,707,058 |
| PEERS TOTAL | 18,615 | 761,901 | -802,810 |
Sign in to see all peers for Bright Minds Biosciences Inc .
Bright Minds Biosciences Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 491 companies in Bright Minds Biosciences Inc's industry classification, broader than the peer set above. Market cap in millions of $.Bright Minds Biosciences Inc ranks #252 of 491 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 988, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,280,038 | 23.96 % |
| 2 | Johnson and Johnson | 685,131 | 12.82 % |
| 3 | Abbvie Inc | 520,479 | 9.74 % |
| 4 | Merck and Co Inc | 365,659 | 6.84 % |
| 5 | Novartis Ag | 1,234 | 5.2% |
| 6 | Abbott Laboratories | 1,234 | 5.2% |
| 7 | Novo Nordisk A | 1,234 | 5.2% |
| 8 | Pfizer Inc | 1,234 | 5.2% |
| 9 | Astrazeneca Plc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 252 | Bright Minds Biosciences Inc | 156 | 0.00 % |
Market cap and industry share for the rest of Bright Minds Biosciences Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-10.
Bright Minds Biosciences Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 247 | Onkure Therapeutics Inc | 169 | 6.46 % |
| 248 | Oramed Pharmaceuticals Inc | 169 | 78.08 % |
| 249 | Sionna Therapeutics Inc | 167 | -89.84 % |
| 250 | Xilio Therapeutics Inc | 166 | - |
| 251 | Equillium Inc | 1,234 | 12.3% |
| 252 | Bright Minds Biosciences Inc | 156 | -58.42 % |
| 253 | Macrogenics Inc | 1,234 | 12.3% |
| 254 | Alx Oncology Holdings Inc | 1,234 | 12.3% |
| 255 | Evotec Se | 1,234 | 12.3% |
| 256 | Akebia Therapeutics Inc | 1,234 | 12.3% |
| 257 | Atrium Therapeutics Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Bright Minds Biosciences Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-10. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Bright Minds Biosciences Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (446 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.5x | - |
| EV / EBITDA | - | 15.4x | - |
| P/B | 4.2x | 4.2x | 0.0x |
| Return on Equity | -14.91 % | industry aggregate | -32.50 % |
| Return on Invested Capital | -7.68 % | -9.78 % (avg) | 2.10 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Bright Minds Biosciences Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Bright Minds Biosciences Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.3% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Bright Minds Biosciences Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 988 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Bright Minds Biosciences Inc's dedicated Suppliers and Customers pages, not here.
Bright Minds Biosciences Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Bright Minds Biosciences Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Bright Minds Biosciences Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 32.5 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
- A meaningful share of competitors (57.10 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-10.1% annualized).
Methodology: see Methodology: SWOT Analysis.
Bright Minds Biosciences Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Bright Minds Biosciences Inc | 35.50 | 36.10 | - |
| Indivior Pharmaceuticals Inc | 0.23 | 0.74 | - |
| Xenon Pharmaceuticals Inc | 5.87 | 18.75 | - |
| Definium Therapeutics Inc | 3.23 | 5.69 | 0.10 |
| Ataibeckley Inc | 3.50 | 9.64 | 0.03 |
| Compass Pathways Plc | 1.36 | 1.52 | 0.40 |
Sign in to see all peers for Bright Minds Biosciences Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Bright Minds Biosciences Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Bright Minds Biosciences Inc | Q3 2025 | - | - |
| Indivior Pharmaceuticals Inc | Q3 2026 | +13.7 % | +226.2 % |
| Xenon Pharmaceuticals Inc | Q2 2026 | - | - |
| Definium Therapeutics Inc | Q2 2026 | - | - |
| Ataibeckley Inc | Q2 2026 | +137.0 % | - |
| Compass Pathways Plc | Q3 2026 | - | - |
| PEERS TOTAL | +33.9 % | - |
Sign in to see all peers for Bright Minds Biosciences Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Bright Minds Biosciences Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Bright Minds Biosciences Inc | Q3 2025 | - | - |
| Indivior Pharmaceuticals Inc | Q3 2026 | -38.6 % | -30.0 % |
| Xenon Pharmaceuticals Inc | Q2 2026 | - | +75.2 % |
| Definium Therapeutics Inc | Q2 2026 | - | - |
| Ataibeckley Inc | Q2 2026 | - | - |
| Compass Pathways Plc | Q3 2026 | - | - |
Sign in to see all peers for Bright Minds Biosciences Inc .
Bright Minds Biosciences Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Bright Minds Biosciences Inc | - | - | - |
| Indivior Pharmaceuticals Inc | 36.35% | 108.22% | - |
| Xenon Pharmaceuticals Inc | - | - | - |
| Definium Therapeutics Inc | - | - | - |
| Ataibeckley Inc | - | - | - |
| Compass Pathways Plc | - | - | - |
Sign in to see all peers for Bright Minds Biosciences Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Bright Minds Biosciences Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Bright Minds Biosciences Inc | - | - |
| Indivior Pharmaceuticals Inc | 8.48 | 3.22 |
| Xenon Pharmaceuticals Inc | - | 313.02 |
| Definium Therapeutics Inc | - | - |
| Ataibeckley Inc | - | 592.79 |
| Compass Pathways Plc | - | - |
| PEERS AVERAGE | - | 10.96 |
Sign in to see all peers for Bright Minds Biosciences Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.